BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Reis TAR, Oliveira-da-Silva JA, Tavares GSV, Mendonça DVC, Freitas CS, Costa RR, Lage DP, Martins VT, Machado AS, Ramos FF, Silva AM, Ludolf F, Antinarelli LMR, Brito RCF, Chávez-Fumagalli MA, Humbert MV, Roatt BM, Coimbra ES, Coelho EAF. Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasis. Exp Parasitol 2021;221:108059. [PMID: 33338468 DOI: 10.1016/j.exppara.2020.108059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Gupta S, Vohra S, Sethi K, Gupta S, Bera BC, Kumar S, Kumar R. In vitro anti-trypanosomal effect of ivermectin on Trypanosoma evansi by targeting multiple metabolic pathways. Trop Anim Health Prod 2022;54. [DOI: 10.1007/s11250-022-03228-1] [Reference Citation Analysis]
2 Kerr L, Cadegiani FA, Baldi F, Lobo RB, Assagra WLO, Proença FC, Kory P, Hibberd JA, Chamie-quintero JJ. Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching. Cureus. [DOI: 10.7759/cureus.21272] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Mendonça DVC, Tavares GSV, Pereira IAG, Oliveira-da-Silva JA, Ramos FF, Lage DP, Machado AS, Carvalho LM, Reis TAR, Carvalho AMRS, Ottoni FM, Ludolf F, Freitas CS, Martins VT, Chávez-Fumagalli MA, Duarte MC, Humbert MV, Roatt BM, Menezes-Souza D, Alves RJ, Coelho EAF. Flau-A, a naphthoquinone derivative, is a promising therapeutic candidate against visceral leishmaniasis: A preliminary study. Exp Parasitol 2021;:108205. [PMID: 34968460 DOI: 10.1016/j.exppara.2021.108205] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Costa RR, Oliveira-da-Silva JA, Reis TAR, Tavares GSV, Mendonça DVC, Freitas CS, Lage DP, Martins VT, Antinarelli LMR, Machado AS, Bandeira RS, Ludolf F, Santos TTO, Brito RCF, Humbert MV, Menezes-Souza D, Duarte MC, Chávez-Fumagalli MA, Roatt BM, Coimbra ES, Coelho EAF. Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis. Med Microbiol Immunol 2021;210:133-47. [PMID: 33870453 DOI: 10.1007/s00430-021-00707-4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]